Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Medistim ASA's average EBITDA Per Share Growth Rate was 15.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medistim ASA was 25.30% per year. The lowest was -29.00% per year. And the median was 11.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Medistim ASA 5-Year EBITDA Growth Rate Related Terms
FRA:MD1 vs ABT, SYK, MDT: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Medistim ASA's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medistim ASA's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 12.00% mean?
Medistim ASA (FRA:MD1) has a 5-Year EBITDA Growth Rate of 12.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Medistim ASA and its competitors.
Is Medistim ASA's 5-Year EBITDA Growth Rate too high?
Medistim ASA's current 5-Year EBITDA Growth Rate is 12.00%. Overall, Medistim ASA has a GF Score™ of 99/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's 5-Year EBITDA Growth Rate compare to ABT and SYK?
Medistim ASA's 5-Year EBITDA Growth Rate of 12.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Medistim ASA and its competitors. Medistim ASA's current 5-Year EBITDA Growth Rate is 12.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (FRA:MD1) is currently considered Fairly Valued. The stock's GF Value™ is €23.45, compared to a current price of €22.40 — trading 4.5% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 12.00%. Medistim ASA's overall GF Score™ is 99/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medistim ASA (FRA:MD1), the current 5-Year EBITDA Growth Rate is 12.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (FRA:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €22.40 is trading 4.5% below its estimated GF Value™ of €23.45.
GuruFocus considers Medistim ASA to be Fairly Valued.
Key valuation signals for FRA:MD1:
5-Year EBITDA Growth Rate: 12.00%
GF Value™: €23.45 vs. price of €22.40 (4.5% below fair value)
No single metric tells the full story. See the FRA:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
99GF Score
Get the complete analysis for FRA:MD1
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MD1 has been successfully added to your 
